These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 31039251)
61. Clinical and prognostic importance of serotyping Mycobacterium avium-Mycobacterium intracellulare complex isolates in human immunodeficiency virus-negative patients. Maekura R; Okuda Y; Hirotani A; Kitada S; Hiraga T; Yoshimura K; Yano I; Kobayashi K; Ito M J Clin Microbiol; 2005 Jul; 43(7):3150-8. PubMed ID: 16000428 [TBL] [Abstract][Full Text] [Related]
62. Contributions of animal and macrophage models to the understanding of host parasite interaction of Mycobacterium avium complex (MAC) disease. Gangadharam PR; Reddy MV Res Microbiol; 1994; 145(3):214-24. PubMed ID: 7809475 [No Abstract] [Full Text] [Related]
63. Two faces of MAC-induced lung disease. Tetenta S; Abunasser J; Bandyopadhyay T Conn Med; 2008 Apr; 72(4):203-5. PubMed ID: 18478985 [TBL] [Abstract][Full Text] [Related]
64. Successful treatment of ulcerative bronchiolitis in a woman with refractory Mycobacterium intracellulare infection. Egan JP; Seides BJ; Olivier KN; Addrizzo-Harris D BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25926588 [TBL] [Abstract][Full Text] [Related]
65. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Kohno Y; Ohno H; Miyazaki Y; Higashiyama Y; Yanagihara K; Hirakata Y; Fukushima K; Kohno S Antimicrob Agents Chemother; 2007 Nov; 51(11):4071-6. PubMed ID: 17709469 [TBL] [Abstract][Full Text] [Related]
66. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China. Zhang Z; Pang Y; Wang Y; Cohen C; Zhao Y; Liu C Int J Antimicrob Agents; 2015 May; 45(5):491-5. PubMed ID: 25795316 [TBL] [Abstract][Full Text] [Related]
67. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis. Park Y; Lee EH; Jung I; Park G; Kang YA Respir Res; 2019 Dec; 20(1):286. PubMed ID: 31852452 [TBL] [Abstract][Full Text] [Related]
68. Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease. Jhun BW; Moon SM; Kim SY; Park HY; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Chung MJ; Lee KS; Shin SJ; Daley CL; Koh WJ Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203483 [TBL] [Abstract][Full Text] [Related]
69. Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice. Bermudez LE; Inderlied CB; Kolonoski P; Chee CB; Aralar P; Petrofsky M; Parman T; Green CE; Lewin AH; Ellis WY; Young LS Antimicrob Agents Chemother; 2012 Aug; 56(8):4202-6. PubMed ID: 22615290 [TBL] [Abstract][Full Text] [Related]
70. Correlation of drug exposure and bacterial susceptibility with treatment response for Zheng X; Wang L; Davies Forsman L; Zhang Y; Chen Y; Luo X; Liu Y; Bruchfeld J; Hu Y; Alffenaar JC; Sha W; Xu B BMJ Open; 2023 Oct; 13(10):e075383. PubMed ID: 37788924 [TBL] [Abstract][Full Text] [Related]
71. Clinical significance of isolation of Mycobacterium avium complex from respiratory specimens. Shen MC; Lee SS; Huang TS; Liu YC J Formos Med Assoc; 2010 Jul; 109(7):517-23. PubMed ID: 20654791 [TBL] [Abstract][Full Text] [Related]
72. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex. Maurer FP; Pohle P; Kernbach M; Sievert D; Hillemann D; Rupp J; Hombach M; Kranzer K Clin Microbiol Infect; 2019 Mar; 25(3):379.e1-379.e7. PubMed ID: 29906595 [TBL] [Abstract][Full Text] [Related]
74. Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model. Ferro BE; Srivastava S; Deshpande D; Sherman CM; Pasipanodya JG; van Soolingen D; Mouton JW; van Ingen J; Gumbo T Antimicrob Agents Chemother; 2015 Dec; 60(3):1242-8. PubMed ID: 26643339 [TBL] [Abstract][Full Text] [Related]
75. Evaluating amikacin minimum inhibitory concentration in trailing growth for Mycobacterium avium complex. Park B; Shim TS; Jo KW; Won EJ; Kim MN; Sung H Tuberculosis (Edinb); 2023 Dec; 143():102427. PubMed ID: 37918057 [TBL] [Abstract][Full Text] [Related]
76. [Clinical features and treatment history of clarithromycin resistance in M. avium-intracellulare complex pulmonary disease patients]. Kuwabara K; Tsuchiya T Nihon Kokyuki Gakkai Zasshi; 2007 Aug; 45(8):587-92. PubMed ID: 17763685 [TBL] [Abstract][Full Text] [Related]
77. Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species. Boyle DP; Zembower TR; Reddy S; Qi C Am J Respir Crit Care Med; 2015 Jun; 191(11):1310-7. PubMed ID: 25835090 [TBL] [Abstract][Full Text] [Related]
78. Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. Hafner R; Inderlied CB; Peterson DM; Wright DJ; Standiford HC; Drusano G; Muth K J Infect Dis; 1999 Aug; 180(2):438-47. PubMed ID: 10395860 [TBL] [Abstract][Full Text] [Related]
79. The association between erythromycin monotherapy for Mycobacterium avium complex lung disease and cross-resistance to clarithromycin: A retrospective case-series study. Hosono Y; Kitada S; Yano Y; Mori M; Miki K; Miki M; Yoshimura K; Kagawa H; Oshitani Y; Yokota S J Infect Chemother; 2018 May; 24(5):353-357. PubMed ID: 29361415 [TBL] [Abstract][Full Text] [Related]
80. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Moon SM; Park HY; Kim SY; Jhun BW; Lee H; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Koh WJ Antimicrob Agents Chemother; 2016 Nov; 60(11):6758-6765. PubMed ID: 27572413 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]